Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. EGFR TKIs induce dramatic objective responses and increase survival in patients bearing sensitizing mutations in the EGFR intr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Noto, Alessia, De Vitis, Claudia, Roscilli, Giuseppe, Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Luberto, Laura, D'Andrilli, Antonio, Coluccia, Pierpaolo, Giovagnoli, Maria Rosaria, Normanno, Nicola, Ruco, Luigi, Aurisicchio, Luigi, Mancini, Rita, Ciliberto, Gennaro
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2013
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://ncbi.nlm.nih.gov/pubmed/23896512
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia